A carregar...

Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells

PURPOSE: Increasing evidence suggests that tear hyperosmolarity is a central mechanism causing ocular surface inflammation and damage in dry eye disease. Mapracorat (BOL-303242-X) is a novel glucocorticoid receptor agonist currently under clinical evaluation for use in the treatment of dry eye disea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cavet, Megan E., Harrington, Karen L., Ward, Keith W., Zhang, Jin-Zhong
Formato: Artigo
Idioma:Inglês
Publicado em: Molecular Vision 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2932489/
https://ncbi.nlm.nih.gov/pubmed/20824100
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!